Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

VK2735

VENTURE

Viking Therapeutics · Phase 2 · Completed · Enrollment 176

NCT06068946

The paper states the 2.5 mg and 15 mg ends of the weekly range, and the placebo result. It does not state each intermediate dose in the abstract cited here, so those registry arms stay n/r.

ArmPopulationDoseWeeksEstimandWeight change
VK2735 (Placebo)Population n/rn/rn/rn/rn/r
VK2735 (Dose #1)Population n/rn/rn/rn/rn/r
VK2735 (Dose #2)Population n/rn/rn/rn/rn/r
VK2735 (Dose #3)Population n/rn/rn/rn/rn/r
VK2735 (Dose #4)Population n/rn/rn/rn/rn/r
VK2735 2.5 mgObesity, no T2D2.5 mg13n/r-9.1% at week 13
VK2735 15 mgObesity, no T2D15 mg13n/r-14.7% at week 13
Placebo 13 weeksObesity, no T2Dn/r13n/r-1.7% at week 13